The FDA issued draft guidance to help pharmaceutical companies and researchers identify an optimal dose of an investigational agent instead of determining its maximum tolerated dose. The recommendations cover collecting and interpreting data, trial design, safety monitoring, premarket dosing, and future indications.

You do not currently have access to this content.